0QW5 Stock Overview
Heidelberg Pharma AG, a biopharmaceutical company, focuses on oncology and antibody targeted amanitin conjugates (ATAC) in Germany, other European countries, the United States, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Heidelberg Pharma AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €2.99 |
| 52 Week High | €4.01 |
| 52 Week Low | €2.62 |
| Beta | -0.31 |
| 1 Month Change | -0.66% |
| 3 Month Change | -11.28% |
| 1 Year Change | -27.78% |
| 3 Year Change | -59.65% |
| 5 Year Change | -5.23% |
| Change since IPO | -89.21% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0QW5 | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0% | 0.5% | 2.7% |
| 1Y | -27.8% | -29.8% | 0.3% |
Return vs Industry: 0QW5 exceeded the UK Biotechs industry which returned -30.5% over the past year.
Return vs Market: 0QW5 underperformed the UK Market which returned -1.8% over the past year.
Price Volatility
| 0QW5 volatility | |
|---|---|
| 0QW5 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 7.1% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 11.3% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: 0QW5 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 0QW5's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 95 | Andreas Pahl | heidelberg-pharma.com |
Heidelberg Pharma AG, a biopharmaceutical company, focuses on oncology and antibody targeted amanitin conjugates (ATAC) in Germany, other European countries, the United States, and internationally. Its lead product candidate is HDP-101, which in the Phase I/IIa study for the treatment of relapsed or refractory multiple myeloma. The company is developing HDP-102 for the treatment of non-Hodgkin lymphoma; HDP-103, an ATAC candidate to treat metastatic castration-resistant prostate cancer; HDP-104 for the treatment of gastrointestinal tumors.
Heidelberg Pharma AG Fundamentals Summary
| 0QW5 fundamental statistics | |
|---|---|
| Market cap | €139.81m |
| Earnings (TTM) | -€20.35m |
| Revenue (TTM) | €9.86m |
14.2x
P/S Ratio-6.9x
P/E RatioIs 0QW5 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0QW5 income statement (TTM) | |
|---|---|
| Revenue | €9.86m |
| Cost of Revenue | €3.25m |
| Gross Profit | €6.61m |
| Other Expenses | €26.95m |
| Earnings | -€20.35m |
Last Reported Earnings
Nov 30, 2023
Next Earnings Date
Jul 11, 2024
| Earnings per share (EPS) | -0.44 |
| Gross Margin | 67.01% |
| Net Profit Margin | -206.38% |
| Debt/Equity Ratio | 11.4% |
How did 0QW5 perform over the long term?
See historical performance and comparison